GenMont Biotech (TPE:3164) Beta: -0.0659 (As of Jul. 08, 2026)


TPE:3164 GenMont Biotech Inc TPE:3164
82 GF Score
Price NT$16.55
GF Value NT$26.24
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GenMont Biotech Beta?

GenMont Biotech TPE:3164 +0.30% 82 Beta is -0.0659 as of Jul. 08, 2026. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-08), GenMont Biotech's Beta is -0.0659.


GenMont Biotech  (TPE:3164) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


GenMont Biotech Beta Related Terms


GenMont Biotech Beta Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech Beta Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.38 0.29 0.19 0.00

GenMont Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.00 0.00 0.00 0.00

TPE:3164 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, GenMont Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMont Biotech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenMont Biotech's Beta distribution charts can be found below:

* The bar in red indicates where GenMont Biotech's Beta falls into.


TPE:3164
82GF Score
GenMont Biotech Inc TPE:3164
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0659 mean?
GenMont Biotech (TPE:3164) has a Beta of -0.0659 as of Jul. 08, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for GenMont Biotech and its competitors.
Is GenMont Biotech's Beta too high?
GenMont Biotech's current Beta is -0.0659. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Beta compare to VRTX and REGN?
GenMont Biotech's Beta of -0.0659 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for GenMont Biotech and its competitors. GenMont Biotech's current Beta is -0.0659. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current Beta is -0.0659. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Beta is -0.0659 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24. GuruFocus considers GenMont Biotech to be Significantly Undervalued.

Key valuation signals for TPE:3164:

  • Beta: -0.0659
  • GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score

Get the complete analysis for TPE:3164

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.55
Price
NT$26.24
GF Value